500013-36-5

Usage

Molecular structure

A chemical compound consisting of a piperazine ring, a carboxylic acid group, and a 4-[(3-hydroxyphenyl)methyl] side chain.

Usage

Primarily used as a building block in the synthesis of pharmaceuticals and other organic compounds.

Potential applications

May have applications in medicinal chemistry and drug design.

Modulating biological activity

The 1-piperazinecarboxylic acid moiety is known for its role in modulating biological activity.

Pharmacological properties

The 4-[(3-hydroxyphenyl)methyl] group may contribute to the compound's pharmacological properties.

Reactivity in chemical reactions

The 4-[(3-hydroxyphenyl)methyl] group may also affect the compound's reactivity in chemical reactions.

Versatility

1-piperazinecarboxylic acid, 4-[(3-hydroxyphenyl)methyl]is a versatile chemical for various scientific and industrial purposes.

Upstream product

• 131362-25-9 [3-(bromomethyl)-phenoxy]dimethyl(1,1-dimethylethyl)silane 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 100-83-4 meta-hydroxybenzaldehyde 

Downstream Products

• 1230021-88-1 4-[3-(3-cyano-pyridin-2-yloxy)-benzyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 523980-09-8 1-(3-(benzyloxy)benzyl)piperazine 
• 1008775-02-7 tert-butyl 4-(3-(benzyloxy)benzyl)piperazine-1-carboxylate 
• 1093211-94-9 4-[3-(pyrimidin-2-yloxy)-benzyl]-piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Indoles and 1-(3-(benzyloxy)benzyl)piperazines: Reversible and selective monoamine oxidase B inhibitors identified by screening an in-house compound library

The therapeutic indications for monoamine oxidases A and B (MAO-A and MAO-B) inhibitors that have emerged from biological studies on animal and cellular models of neurological and oncological diseases have focused drug discovery projects upon identifying

HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

benzamide derivatives as oxytocin agonists and vasopressin antagonists

Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or Via receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.